XLO - NASDAQ

Xilio Therapeutics, Inc.

XLO·NASDAQ

$8.46

-0.71%

HealthcareBiotechnology

Xilio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies to improve the immune system of cancer patients. Its checkpoint inhibitor program includes XTX101, a clinical-stage, tumor-selective anti-CTLA-4 mAb that is in Phase 1/2 clinical trials in patients with solid tumors. The company also develops cytokine programs, which comprises XTX202, a modified form of IL-2; XTX301, an IL-12 product candidate; and XTX401, an IL-15 product candidate that are masked with a protein domain to prevent binding activity until cleaved off by tumor microenvironment (TME)-associated proteases. Xilio Therapeutics, Inc. was founded in 2016 and is headquartered in Waltham, Massachusetts.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$50.61M

EPS-4.1900

P/E Ratio-21.38

Earnings Date08/13/2026

154.69M

Assets

118%

3Y+11.0%

5Y+326.0%

10Y+147.0%

119.41M

Total Liabilities

123%

3Y+256.0%

5Y+187.0%

10Y+393.0%

35.27M

Total Equity

100%

3Y-67.0%

5Y-767.0%

10Y-8.0%

Xilio Therapeutics, Inc. Funding & Solvency Profile

XLO · NASDAQ

Current Assets

Cash & Cash Equivalents137.53M

Net Receivables5.00M

Inventory0.00

Other Current Assets2.50M

Total Current Assets145 M

Non-Current Assets

Property, Plant & Equipment7.85M

Goodwill & Intangible Assets0.00

Long-Term Investments1.81M

Other Non-Current Assets0.00

Total Non-Current Assets10 M

Total Assets

154.69M

Financial Health Analysis

Current Ratio

2.58x

Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.

Debt-to-Equity Ratio

3.39x

High financial leverage. Heavy reliance on debt may indicate increased financial risk and potential solvency concerns.

Working Capital

89 M

Strong working capital position provides significant operational flexibility and financial cushion.

Asset Composition

94% Current

Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.

Financial Health Insight

Mixed signals: Strong short-term liquidity provides comfort, but high overall leverage requires careful monitoring of debt servicing capabilities and refinancing risk.

Xilio Therapeutics, Inc. Balance Sheet

XLO • NASDAQ

Xilio Therapeutics, Inc. Balance Sheet	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	137.5M	55.3M	44.7M	120.4M	198.1M	19.2M	48.8M
Cash & Short-Term Investments	137.5M	55.3M	44.7M	120.4M	198.1M	19.2M	48.8M
Net Receivables	5M	0.0	0.0	0.0	0.0	0.0	0.0
Accounts Receivables	5M	0.0	0.0	0.0	0.0	0.0	0.0
Prepaids	0.0	0.0	0.0	0.0	0.0	1.4M	1.3M
Other Current Assets	2.5M	4.9M	3.4M	4.1M	4.5M	0.0	1M
Total Current Assets	145M	60.2M	48.1M	124.5M	202.5M	20.6M	51.1M
NON-CURRENT ASSETS
Property, Plant, and Equipment (Net)	7.9M	9.1M	11.2M	12.8M	13.9M	14.1M	9.9M
Long-Term Investments	1.8M	1.8M	0.0	1.6M	1.6M	0.0	194K
Tax Assets	0.0	0.0	0.0	0.0	3.5M	0.0	0.0
Other Non-Current Assets	0.0	0.0	1.6M	267K	90K	1.7M	1.6M
Total Non-Current Assets	9.7M	10.8M	12.8M	14.7M	19.1M	15.7M	11.6M
Total Assets	154.7M	71.1M	60.9M	139.2M	221.6M	36.3M	62.7M
LIABILITIES
CURRENT LIABILITIES
Total Payables	3.2M	2.6M	1.1M	3.1M	3.1M	5.4M	2.5M
Accounts Payable	3.2M	2.6M	1.1M	3.1M	3.1M	5.4M	2.5M
Accrued Expenses	0.0	5.8M	4.7M	10.3M	5.1M	13.7M	769K
Short Term Debt	1.3M	0.0	3.3M	6.7M	883K	2.3M	0.0
Capital Lease Obligations (Current)	0.0	1.2M	0.0	918K	0.0	646K	0.0
Deferred Revenue	40M	13.5M	0.0	0.0	0.0	0.0	0.0
Other Current Liabilities	11.7M	4.2M	6.9M	82K	3.6M	0.0	1.9M
Total Current Liabilities	56.3M	27.3M	16M	21.1M	12.8M	22.2M	5.2M
NON-CURRENT LIABILITIES
Long Term Debt	0.0	0.0	0.0	3.2M	9.6M	7.8M	9.6M
Deferred Revenue (Non-Current)	0.0	19.3M	0.0	0.0	0.0	0.0	0.0
Deferred Tax Liabilities (Non-Current)	0.0	0.0	0.0	0.0	3.5M	0.0	0.0
Other Non-Current Liabilities	57.5M	0.0	0.0	45K	0.0	540K	374K
Total Non-Current Liabilities	63.1M	26.2M	8.1M	12.4M	23.4M	19.4M	19M
Capital Lease Obligations	5.6M	8.1M	8.1M	10.1M	10.2M	11.7M	9M
Total Liabilities	119.4M	53.5M	24.1M	33.5M	36.2M	41.6M	24.2M
SHAREHOLDERS' EQUITY
Preferred Stock	0.0	0.0	0.0	0.0	0.0	78M	68M
Common Stock	36.9M	5K	3K	3K	3K	0.0	0.0
Additional Paid-In Capital	0.0	401.3M	0.0	354.8M	346.3M	1.8M	344K
Retained Earnings	-418.8M	-383.8M	-325.5M	-249.1M	-160.9M	-85.1M	-29.9M
Other Total Stockholders' Equity	417.2M	0.0	362.3M	0.0	0.0	0.0	0.0
Total Stockholders' Equity	35.3M	17.6M	36.8M	105.6M	185.4M	-5.3M	38.5M
Total Equity	35.3M	17.6M	36.8M	105.6M	185.4M	-5.3M	38.5M
SUMMARY
Total Liabilities & Equity	154.7M	71.1M	60.9M	139.2M	221.6M	36.3M	62.7M
Total Investments	1.8M	1.8M	0.0	1.6M	1.6M	0.0	194K
Total Debt	7M	8.1M	11.5M	19.9M	20.7M	21.9M	18.6M
Net Debt	-130.6M	-47.1M	-33.2M	-100.4M	-177.3M	2.6M	-30.2M
Shares Outstanding	5,782,510	5,782,510	5,782,510	5,782,510	5,782,510	5,782,510	5,782,510

SEC Filings

XLO - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
S-3/A S-3/A (Amended) N/A	May 27, 2026	May 27, 2026		View Filing
8-K 8-K 2026 N/A	May 12, 2026	May 12, 2026	2026	View Filing
10-Q 10-Q 2026 Q1 Q1	May 12, 2026	March 31, 2026	2026	View Filing
S-3 S-3 N/A	May 12, 2026	May 12, 2026		View Filing
DEF 14A DEF 14A 2026 N/A	April 28, 2026	June 10, 2026	2026	View Filing
8-K 8-K 2026 N/A	April 16, 2026	April 15, 2026	2026	View Filing
10-K 10-K 2025 FY FY	March 23, 2026	December 31, 2025	2025	View Filing
8-K 8-K 2026 N/A	March 23, 2026	March 23, 2026	2026	View Filing
8-K 8-K 2026 N/A	March 12, 2026	March 12, 2026	2026	View Filing
8-K 8-K 2026 N/A	March 09, 2026	March 09, 2026	2026	View Filing

Showing 1 to 10 of 101 filings

Related Guides

Blog Categories

Continue your XLO research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.